Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164991 | 0.84 | GRM2 (0.41) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL161307 | 0.82 | NT5E (0.32) | NT5E | |
| SCHEMBL163749 | 0.81 | KDM4E (0.44) | MEN1KMT2AMPOKDM4EMAPT | |
| SCHEMBL162442 | 0.81 | PTGES (0.35) | MPONT5EF2 | |
| SCHEMBL164199 | 0.80 | CCNE2 (0.41) | MEN1KMT2AKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28094499 | 0.80 | KDM4E (0.43) | MEN1KMT2AMPOKDM4EMAPT | |
| SCHEMBL27845976 | 0.78 | PSEN1 (0.39) | MEN1KMT2AKDM4EMAPTF2 | |
| SCHEMBL161366 | 0.77 | KDM4E (0.43) | MEN1KMT2AKDM4EMAPT | |
| SCHEMBL27845975 | 0.77 | PKM (0.38) | KMT2AKDM4EMAPTF2 | |
| SCHEMBL28094522 | 0.75 | GRM2 (0.34) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225578-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2611448-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030912-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225578-A1 | 7-CYCLYLQUINAZOLINE DERIVATIVES AND METHODS OF USE THEREOF | JAK2, JAK3, TYK2 | MEN1 3010/4885KMT2A 1014/4885MPO 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.